FDA Urges Analysis of Covariance for Randomized Control Trials

Drug Industry Daily
A A
Drug sponsors can use complicated covariance analyses to help determine statistical significances or to help sharpen estimates of how well a treatment might work but they shouldn’t apply those analyses to anything in a clinical trial that might be affected by treatment, the FDA says in a new draft guidance document issued Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily